


# DATA ANALYSIS AND VISUALIZATION

## PIPELINE OF ANTIMICROBIAL AGENTS IN CLINICAL DEVELOPMENT (WHO – NOV 2021)

### CONTRIBUTORS


Adaradohun Samson (@Adara); Nwokocha Amarachi (@Amara);  
Lakshana Bakthavachalam (@Lakshana); Astrid Liliana Vargas Sanchez (@Liliana);  
Mahesh Rani Kamilus (@Mahesh)

### ANTIMICROBIAL PRODUCT – TYPES




A total of 80 antimicrobial products.  
46 - Antibiotics; 34 - Non-traditional

### TARGET PATHOGENS



Most targeted pathogen - *Staphylococcus aureus*.  
Least targeted pathogen - *Mycobacterium tuberculosis*.

### SPECTRUM OF ANTIMICROBIAL PRODUCTS AGAINST PATHOGENS




The spectrum of antimicrobial products are broad against **priority pathogens**. However, only **limited** number of antibiotics and non-traditional are effective against *Mycobacterium tuberculosis* and *Clostridium difficile*.

More antibiotics target *Mycobacterium tuberculosis* when compared to non-traditional. The reverse holds true for *Clostridium difficile*.

### ANTIBACTERIAL INDICATIONS


An antimicrobial indication refers to specific condition or infection for which an antimicrobial agent is recommended or prescribed.

### PRIORITY LEVEL OF PATHOGENS



Critical priority pathogens pose urgent threat due to its high AMR. Pathogens like *Pseudomonas aeruginosa*, *Enterobacteriales*, *Acinetobacter baumannii* falls under this category.

### CLINICAL DEVELOPMENT PHASE OF ANTIMICROBIAL PRODUCTS




#### Antibiotics

#### Non-traditional

Phase I	22
Phase II	14
Phase III	9
Pre-registration	1

Phase I	12
Phase II	15
Phase III	5
Pre-registration	2

### ROUTE OF ADMINISTRATION



Oral is the most preferred route of administration.

### INNOVATIVENESS

INNOVATIVE	PRODUCTS (in numbers)
Yes	17
No	23
Inconclusive	6
NA	34